1.Study on Pharmacokinetics of Aclacinomycin A Polylactide Lyophilized Nanoparticle in Plasma of Rabbit
China Pharmacy 2001;12(2):80-81
OBJECTIVE:To study the pharmacokinetics of aclacinomycin A polylactide lyophilized nanopartical (ACM-A-PLA-NP) in plasma of rabbit.METHODS:HPLC was selected to determine the concentration of aclacinomycin A in plasma after a single dose of ACM-A-PLA-NP and lyophilized ACM-A.RESULTS:The pharmacokinetic parameters of these two dosage forms were obtained by 3p87.CONCLUSION:The lyophilized ACM-A-PLA-NP has a more sustained release character comparing with the lyophilized ACM-A.
2.Evidence-based Pharmacy in Clinical Pharmaceutical Practice
China Pharmacy 2001;12(2):75-77
AIM:To introduce evidence-based pharmacy in respect to the definition,contents and principle in applying to decisions of clinical pharmacotherapy.METHODS:We focused the discussion on a brief summary of different study designs,factors affecting the strength of scientific evidence,and interpretation of the data.RESULTS:These application principles are helpful to guide clinical pharmacists solving clinical problems.CONCLUSION:Clinical pharmacist should use concepts in the evidence-based practice when making pharmacotherapeutic decisions in the future.
3.Study on Quality Control Method for Renshensinitang Oral Liquid(Radix Ginseng,Radix Aconiti Praeparata,etc.)
Chinese Traditional Patent Medicine 1992;0(11):-
This paper reported TLC identification of various Chinese medicines in Renshensinitang Oral Liq- uid,limit dose detection and content determination of aconitine.These methods could be available for internal quality control of Renshensinitang Oral Liquid.
4.Content Determination of Paeoniflorin in Blood Plasma with Reversed-phase High-efficiency Liquid Chromatography
Chinese Traditional Patent Medicine 1992;0(02):-
The method, established for analysis of paeoniflorin in blood plasma, appeared a good linear relationship(r=0.9998). Using meta-hydroxybenzoic acid as internal standard and calibration factor combined, the quantitation precision of method could be raised. The result of determination of calibration factor conformed with the chromatography prescriptions in "Pharmacopoeia of China" (edited in 1990). The average recovery reached up 97.13%. The minimum detection amount was 5.6ng. The coefficients of within-day and between-day variation were 0.39% and 1.17%, respectively. This method is suitable for paeoniflorin analysis of in vivo sample . At present,the in vivo absorption of Baihegujintang Granules (containing Radix Paeoniae alba or Radix Paeoniae rubra) by rabbit is preliminarily investigated utilizing this method.
5.Mechanism of intestinal absorption of tetrandrine in rats
Chinese Traditional and Herbal Drugs 1994;0(02):-
duodenum, respectively. Conclusion The absorption of tetrandrine is first-order process with passive diffusion mechanism. Tetrandrine is well absorbed at all segments of intestine in rats.
6.Survey of Status Quo of Hospital Pharmaceutical Services and Clinical Pharmacy in China (Part 1): General Situation of Hospital Pharmaceutical Services
China Pharmacy 1991;0(01):-
OBJECTIVE: To comprehend the general situation of pharmaceutical services in hospitals in China.METHOD: The general situation of pharmaceutical services was investigated by questionnaire survey through mailing among a total of 600 hospitals including third-level grade A and B and second-level grade A and B hospitals and 42 pilot sites hospitals of clinical pharmacist work system selected by stratified random sampling.And the results were given a statistical analysis.RESULTS & CONCLUSIONS: A total of 281 questionnaires(46.8%) were sent back from sample hospitals and 29(69.0%) from pilot hospitals.37.1% of the hospitals developed the service of mixed dispensing for intravenous drugs,61.7% set up drug information consultation department,32.9% had monitoring software or system for rational drug use,indicating a great evolvement has been achieved in Chinese hospital pharmaceutical services.But there is still great difference in pharmaceutical care between different level and grade of hospitals.
7.Analysis of Psychotolytics Used in Guangdong during the Period of 2000~2004
China Pharmacy 2001;0(07):-
OBJECTIVE:To study the use and developmental tendency of psychotolytics in hospitals of Guangdong province.METHODS:The psychotolytics used in hospitals of Guangdong province during the period of2000~2004were an-alyzed statistically in respect to consumption sum,DDDs and average daily expense.RESULTS&CONCLUSIONS:Both consumption sum and DDDs of psychotolytics in the past5years increased to a large extent.Benzodiazepine topped the list of anti-anxiety drugs.The consumption of2nd generation antipsychotics increased year by year.On the whole,the consumption of antidepressants increased annually,of which,fluoxetine,flupentixol/melitracen and paroxetine were the most frequently used drugs.However,the consumption of tricyclic antidepressants has a significant reduction.
8.Survey on Hospital Pharmaceutical Care in China and the Status Quo of Clinical Pharmacy Practice(Part 2):Survey on Status Quo of Clinical Pharmacy Practice
China Pharmacy 2005;0(13):-
OBJECTIVE: To probe into the status quo of the practice of clinical pharmacy in hospitals of China.METHODS: A mailed questionnaire survey was conducted among 600 sample hospitals and 42 clinical pharmacist work system pilot hospitals based on stratified sampling regarding the status quo of the clinical pharmacy practice in China.And the results were subjected to statistical analysis.RESULTS & CONCLUSIONS: A total of 310 questionnaires were sent back,which revealed that the proportions of developing clinical pharmaceutical services including prescription evaluation,ADR monitoring,drug information consultation in hospitals at different level were high,but the proportions of developing such pharmaceutical services as medication orders' writing and drug-food interaction monitoring were low.The pilot hospitals had better clinical pharmacy services as compared with common hospitals,much as in drug therapy monitoring and individualized medication therapy.The clinical pharmacists were characterized by low quality and scanty numbers.The financial support to clinical pharmacy and the role of the clinical pharmacists remain to be intensified.
9.IMPROVING BIOAVAILABILITY OF NAFTOPIDIL BY USING BIOADHESION IN DOGS
Jinsong DING ; Xuehua JIANG ; Mu YUAN
Acta Pharmaceutica Sinica 2001;36(5):377-380
AIM To prepare naftopidil bioadhesive sustained-release capsule and study their pharmacokinetics and relative bioavailability in the dog. METHODS Bioadhesive polymers such as hydroxypropyl methylcellulse (HPMC) and Carbopol 934 (CP 934) were used in capsule prescriptions. Naftopidil capsule and two formulations of bioadhesive sustained-release capsules (I and II) were given to five healthy male dogs in a cross-over test. The naftopidil concentrations in plasma were determined by a newly developed HPLC method and the pharmacokinetic parameters as well as the relative bioavailability were measured. RESULTS The C0→∞, Cmax and Tmax of naftopidil capsule was (3728±573) h*ng*mL-1, (697±94) ng*mL-1 and (1.2±0.5) h. These parameters of bioadhesive sustained-release capsule I and II, respectively, were (5518±391) h*ng*mL-1 and (5636±427) h*ng*mL-1; (468±61) ng*mL-1 and (512±72) ng*mL-1; both (4.0±0.7) h. Results from statistics showed that there were significant difference between bioadhesive formulations and the non-bioadhesive one in C0→∞, Cmax and Tmax. The bioadhesive formulations and the non-bioadhesive one were not bioequivalent, the relative bioavailability of the two bioadhesive sustained-release capsules were respectively 150%±14% and 154%±23% when compared with the non-bioadhesive capsule. CONCLUSION It is much improving bioavailability of naftopidil by using bioadhesion.
10.Current situations of sterile and implantable medical device manufacturing in Sichuan Province:an investigation in 31 production enterprises
Jing ZHOU ; Xiang YE ; Xuehua JIANG
Chinese Journal of Tissue Engineering Research 2017;21(6):928-933
BACKGROUND:The Specification of Quality Management for Medical Device Production (for Trial Implementation) issued by the China Food and Drug Administration (CFDA) on December 16, 2009 was demanded to be initially implemented in medical device manufacturers with a higher risk in sterility and implant before January 1, 2011. The revised version was published on December 29, 2014 and came into effect on March 1, 2015. OBJECTIVE:To put forward specific suggestions through analyzing the status of 31 sterile implantable medical device manufacturers in Sichuan Province and the corresponding implementation situation of the specification for trial implementation. METHODS:The relevant data of these 31 manufacturers were collected through the quality management system assessment, supervision and inspection, flight inspection and questionnaire survey. And the data were analyzed statistically. RESULTS AND CONCLUSION:The overall size of medical device manufacturers in Sichuan Province is small. There are still some other problems, such as no advanced equipment, low quality of employees, lack of funds and inappropriate management, in these manufacturers. Considering these, we have given some guiding recommendations from the aspects of production and supervision.